Cancer Chemotherapy and Biological Response Modifiers 1992
Annual 13
Published on 17. August 1992
Book
Hardback
690 pages
978-0-444-89683-4 (ISBN)
Description
Several extremely interesting new developments have taken place in clinical cancer research in the past year. Cellular pharmacology of anti-neoplastic agents has continued gathering momentum. More insight has been acquired into the mechanisms of drug resistance where multi-drug resistance (MDR) is the center of interest. It is important in this research to define clinical resistance at the cellular level by using tumor biopsies from patients sensitive or resistant to chemotherapy and MDR reverters. The use of high-dose chemotherapy, as another approach to overcoming drug resistance is proving to be quite successful in lymphomas and is now being tested in chemosensitive tumors. Major emphasis has been put on improving the tolerability of high-dose chemotherapy. G-CSF and GM-CSF have allowed the possibility of delivering significantly higher doses of chemotherapy, achieving higher complete remission rates. Several studies are also investigating the potential role of G-CSF and GM-CSF in myelodisplastic syndromes. The finding that differentiating agents like retinoids are capable of inducing remissions in acute promyelocytic leukemia is extremely exciting.
More details
Edition
New edition
Language
English
Place of publication
Oxford
United Kingdom
Publishing group
Elsevier Science & Technology
Target group
College/higher education
Professional and scholarly
Edition type
New edition
Dimensions
Height: 230 mm
Weight
1750 gr
ISBN-13
978-0-444-89683-4 (9780444896834)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Content
Introduction. I. DRUGS 1. Antimetabolites (E. Chu, et al.). 2. Alkylating agents (T.A. Connors). 3. Anthracyclines (C.E. Myers). 4. Bleomycins (J.S. Lazo, S.M. Sebti). 5. Mitomycin C (N.W. Gibson, D. Siegel, D. Ross). 6. Mitotic inhibitors (B.A. Chabner). 7. Podophyllotoxin derivatives (M. D'Incalci, S. Garattini). 8. Cisplatin (E. Reed). 9. Multidrug resistance (J.A. Moscow, C.S. Morrow, K.H. Cowan). 10. New anticancer agents (T.D. Brown, et al.). II. BIOLOGICAL RESPONSE MODIFIERS 11. Monoclonal antibody therapy (M. Schwartz, D.A. Scheinberg, A.N. Houghton). 12. Biological response modifiers (J.W. Clark). 13. Adoptive cellular therapy (M. Sznol, W.J. Urba). 14. Immunological monitoring and clinical trials of biological response modifiers (M.W. Baseler, W.J. Urba). 15. Growth and differentiation control (G.E. Francis, M. Domine). 16. Differentiating agents in cancer therapy (J. Michaeli, R.A. Rifkind, P.A. Marks). 17. Colony-stimulating factors in cancer therapy (G. Morstyn, W.P. Sheridan). III. TUMORS. 18. Leukemias and plasma cell myeloma (P.H. Wiernik). 19. Lymphomas (D.L. Longo, V.T. DeVita, Jr.). 20. Therapy of AIDS and AIDS-associated neoplasms (J.M. Pluda, S. Broder, R. Yarchoan). 21. Head and neck cancer (S.G. Taylor IV). 22. Lung cancer (H.H. Hansen, M. Rorth). 23. Upper gastrointestinal tumors (M. Ogawa, T. Tagushi). 24. Cancers of the large bowel and hepatobiliary tract (J. Treat, P.V. Woolley III). 25. Endocrine tumors (S.D. Averbuch). 26. Genitourinary cancer (G.R. Hudes, et al.). 27. Gynecological malignancies (R.J. Schilder, S.A. Godfrey, R.C. Young). 28. Breast cancer (H.C. Pitot, C.L. Loprinzi). 29. Malignant melanoma (J.F. Smyth). 30. Soft tissue and bone sarcomas (A. Santoro, G. Bonadonna). 31. Brain tumors (E.A.M.T. Obbens, W.R. Shapiro). 32. Childhood solid tumors (C.B. Pratt). 33. Supportive care (M. Markman). Abbreviations of drugs. Abbreviations of chemotherapeutic combinations. Biological Abbreviations. NSC numbers. Subject index.